FIGURE 2.

A 66‐year‐old female with a 5‐year history of moderate inflammatory rosacea resistant to previous treatment with a topical metronidazole 1% gel (MTZ) applied twice daily. The main reason of consultation was the poor response and persistent irritation by MTZ. Standard (A, B) and erythema‐directed digital photography (C, D) showed after 8 weeks of treatment (B–D) with the novel azelaic acid formulation a significant reduction of IGA score (from 3 to 1), papules count (from 15 to 3) and EDDP score (from 3 to 1) from baseline (A–C) (p < 0.001). Treatment response was excellent with minimal residual background erythema and telangiectasias. No side effects were recorded